Search hospitals > Ontario > HAMILTON
Novartis Investigative Site
Claim this profileHAMILTON, Ontario L8V 5C2
Conducts research for Heart Failure
Conducts research for Leukemia
Conducts research for Myeloid Leukemia
Conducts research for Cancer
Conducts research for Chronic Myelogenous Leukemia
63 reported clinical trials
0 medical researchers
Summary
Novartis Investigative Site is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Heart Failure, Leukemia, Myeloid Leukemia, Cancer, Chronic Myelogenous Leukemia and other specialties. Novartis Investigative Site is involved with conducting 63 clinical trials across 72 conditions. There are 0 research doctors associated with this hospital, such as .Area of expertise
1Heart Failure
2Leukemia
BCR-ABL positive
BCR-ABL1 positive
BCR-ABL1 e13a2 positive
Top PIs
Clinical Trials running at Novartis Investigative Site
Chronic Urticaria
Diffuse Large B-Cell Lymphoma
Hives
Prostate Cancer
Lymphoblastic Leukemia-Lymphoma
B-Cell Lymphoma
Lymphoid Leukemia
Acute Lymphoblastic Leukemia
CAR-T Therapy Safety
Systemic Lupus Erythematosus
Remibrutinib
for Chronic Urticaria
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs). The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data on remibrutinib in participants after having completed the Core period
Recruiting1 award Phase 38 criteria
Remibrutinib
for Hives
The purpose of the core phase of the trial is to assess the efficacy, safety and tolerability of remibrutinib (LOU064) 25 milligrams (mg) twice a day (b.i.d.) over placebo for 24 weeks and in comparison to omalizumab 300 mg every 4 weeks (q4w) for 52 weeks in participants with chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines (H1-AH). The purpose of the open-label extension phase is to assess efficacy, safety and tolerability up to two years for patients treated with remibrutinib and patients transitioned from omalizumab to remibrutinib at Week 52. In the extension phase, treatment will be with remibrutinib only (i.e., no background therapy). The extension phase will also fulfill the Novartis commitment to provide post-trial access to participants of the previous core phase.
Recruiting1 award Phase 37 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Novartis Investigative Site?
Novartis Investigative Site is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Heart Failure, Leukemia, Myeloid Leukemia, Cancer, Chronic Myelogenous Leukemia and other specialties. Novartis Investigative Site is involved with conducting 63 clinical trials across 72 conditions. There are 0 research doctors associated with this hospital, such as .